Literature DB >> 1469702

Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity.

M J Suto1, J M Domagala, G E Roland, G B Mailloux, M A Cohen.   

Abstract

Fluoroquinolones are potent inhibitors of bacterial topoisomerase II (DNA gyrase). They can also inhibit eukaryotic topoisomerases, which could possibly lead to clastogenicity and/or cellular toxicity. Recent studies have demonstrated a correlation between mammalian cell cytotoxicity of the fluoroquinolones and the potential of these compounds to induce micronuclei, a genetic toxicity endpoint. In an effort to identify potent nontoxic quinolone antibacterials, we have examined the structural features of the fluoroquinolones associated with mammalian cell cytotoxicity. An investigation of a wide variety of substituents at the 1, 5, 7, and 8 positions of a quinolone nucleus was conducted. The results indicate that no one position has a controlling effect on the observed cytotoxicity. Instead, a combination of the various substituents contributes to the effects seen. Certain trends were apparent, such as the fact that compounds with pyrrolidines at the R-7 position were more cytotoxic than those with piperazines, and halogens at R-8 (X-position) were associated with more cytotoxicity relative to hydrogen. A general trend also existed between the cytotoxicity of the compounds and their Gram-positive antibacterial activity. A detailed comparison between the various groups and positional variations as they controlled the cytotoxicity and antibacterial activity is presented.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1469702     DOI: 10.1021/jm00103a013

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  14 in total

1.  Investigation of enrofloxacin and chloramphenicol residues in broiler chickens carcasses collected from local markets of tabriz, northwestern iran.

Authors:  Vahideh Ebrahimzadeh Attari; Mehran Mesgari Abbasi; Nasim Abedimanesh; Alireza Ostadrahimi; Abolfazl Gorbani
Journal:  Health Promot Perspect       Date:  2014-12-30

2.  Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position.

Authors:  T E Renau; J W Gage; J A Dever; G E Roland; E T Joannides; M A Shapiro; J P Sanchez; S J Gracheck; J M Domagala; M R Jacobs; R C Reynolds
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

Review 3.  A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.

Authors:  Gregory S Bisacchi; Michael R Hale
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

Review 4.  Comparative tolerability of the newer fluoroquinolone antibacterials.

Authors:  P Ball; L Mandell; Y Niki; G Tillotson
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

5.  Effect of HIV infection and antiretroviral therapy on immune cellular functions.

Authors:  Marek Korencak; Morgan Byrne; Enrico Richter; Bruce T Schultz; Patrick Juszczak; Julie A Ake; Anuradha Ganesan; Jason F Okulicz; Merlin L Robb; Buena de Los Reyes; Sandra Winning; Joachim Fandrey; Timothy H Burgess; Stefan Esser; Nelson L Michael; Brian K Agan; Hendrik Streeck
Journal:  JCI Insight       Date:  2019-06-20

6.  Veterinary antibiotic resistance, residues, and ecological risks in environmental samples obtained from poultry farms, Egypt.

Authors:  Hesham Dahshan; Amr Mohamed Mohamed Abd-Elall; Ayman Mohamed Megahed; Mahdy A Abd-El-Kader; Ehab Elsayed Nabawy
Journal:  Environ Monit Assess       Date:  2015-01-20       Impact factor: 2.513

7.  Novel and Structurally Diversified Bacterial DNA Gyrase Inhibitors Discovered through a Fluorescence-Based High-Throughput Screening Assay.

Authors:  Eddy E Alfonso; Zifang Deng; Daniel Boaretto; Becky L Hood; Stefan Vasile; Layton H Smith; Jeremy W Chambers; Prem Chapagain; Fenfei Leng
Journal:  ACS Pharmacol Transl Sci       Date:  2022-09-02

8.  Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.

Authors:  E Y Ng; M Trucksis; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

9.  Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential.

Authors:  S H Elsea; P R McGuirk; T D Gootz; M Moynihan; N Osheroff
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

10.  Riboswitching with ciprofloxacin-development and characterization of a novel RNA regulator.

Authors:  Florian Groher; Cristina Bofill-Bosch; Christopher Schneider; Johannes Braun; Sven Jager; Katharina Geißler; Kay Hamacher; Beatrix Suess
Journal:  Nucleic Acids Res       Date:  2018-02-28       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.